Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below Two Hundred Day Moving Average of $1.09

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.09 and traded as low as $0.75. Karyopharm Therapeutics shares last traded at $0.76, with a volume of 481,267 shares.

Wall Street Analyst Weigh In

Several equities analysts recently commented on KPTI shares. StockNews.com upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $3.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. Finally, Robert W. Baird dropped their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $4.80.

Karyopharm Therapeutics Stock Performance

The stock has a 50-day simple moving average of $0.88 and a 200-day simple moving average of $1.09.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.09. The firm had revenue of $42.79 million for the quarter, compared to analysts’ expectations of $36.07 million. As a group, equities research analysts forecast that Karyopharm Therapeutics Inc. will post -0.93 EPS for the current year.

Insider Buying and Selling at Karyopharm Therapeutics

In other Karyopharm Therapeutics news, Director Deepika Pakianathan sold 468,044 shares of the business’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $0.96, for a total transaction of $449,322.24. Following the completion of the sale, the director now owns 3,385 shares of the company’s stock, valued at $3,249.60. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 1,074,687 shares of company stock valued at $1,043,723. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of KPTI. Point72 DIFC Ltd purchased a new stake in shares of Karyopharm Therapeutics in the second quarter worth about $31,000. Simplicity Wealth LLC purchased a new stake in shares of Karyopharm Therapeutics in the first quarter worth about $66,000. Monashee Investment Management LLC purchased a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth about $115,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Karyopharm Therapeutics in the second quarter worth about $143,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Karyopharm Therapeutics in the second quarter worth about $167,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).